Category: Health

Mar 30: For decades, the Indian haircare industry has operated on a singular myth: that real repair requires overnight oiling or hours in a salon chair. K formula, a homegrown science-led beauty brand, is dismantling that narrative with India’s first peptide-powered molecular haircare range, delivering visible hair repair in just minutes.

Launched in October 2025, the brand has quickly emerged at the forefront of the growing skinification of haircare movement – a shift where consumers demand skincare-grade ingredients and molecular science for their hair, not just cosmetic shine.

At the heart of the brand is Trichopeptics™ technology, a proprietary peptide system developed over two years in laboratories specifically for Indian hair types, climate conditions, and water quality.

The result is a new promise for consumers: “New Hair in 5 Minutes.”

The Science Behind the 5-Minute Transformation

While the claim may sound bold, the technology is rooted in advanced molecular repair. Traditional conditioners typically coat the hair with silicones that create temporary smoothness. K Formula’s peptide complexes work differently. Powered by Trichopeptics™, the formulas penetrate the polypeptide chain level of the hair fiber, the deepest structural layer where keratin bonds exist.

Damage caused by heat styling, bleach, pollution, UV exposure, and India’s prevalent hard water breaks these chains. K Formula’s peptides reconnect and repair these bonds, reversing visible damage within minutes rather than hours. The result is instant transformation with long-term structural repair.

Riding the Skinification Wave

The global beauty industry is witnessing the skinification of haircare – where hair products borrow the same molecular science, active ingredients, and precision formulations traditionally seen in skincare.

K Formula is among the first Indian brands to bring this movement to the country through peptide-powered molecular repair, transforming haircare from cosmetic maintenance into science-led structural treatment. Instead of temporary smoothness, the focus shifts to repairing the biology of the strand itself.

The Viral ‘5-Minute Hair Challenge’

K Formula’s rapid rise has been fueled not by heavy advertising, but by transparent proof-driven content. The brand’s #5MinuteHairChallenge went viral on Instagram, where users filmed single-take transformations using a live stopwatch to demonstrate visible results. From college students to professional stylists, real users documented the peptide routine in real time, creating a wave of authentic peer validation.

Within weeks, the challenge generated:

• 900,000+ organic reach

• 5,000+ peer-to-peer shares

The viral momentum proved that in a skeptical beauty market, visible proof travels faster than polished advertising.

Market Traction & Professional Validation

Beyond social media momentum, K Formula has rapidly built credibility across both consumer and professional ecosystems.

• 50+ Salon Partnerships across India

• Developed with and endorsed by celebrity hairstylist Sahib Mongia

• Rapidly scaling across its official website, and leading commerce platforms including Amazon, Flipkart, Myntra, and quick-commerce platform Blinkit

Early batches of the peptide-powered routine sold out quickly following viral demand.

A Vision for Science-Led Indian Beauty

Founded by Anoushka Adya, K Formula was created to bridge the gap between global biotech innovation and the real needs of Indian hair.

“Indian consumers deserve haircare built for our climate, water quality, and genetics – not just adapted global formulas. We wanted to build a brand where the results are so immediate that consumers themselves become the marketing engine. When you see molecular repair happen in five minutes on a live timer, you don’t need a sales pitch.” says Anoushka Adya, Founder, K Formula.

As India’s beauty industry moves toward ingredient literacy and scientific formulations, K Formula is positioning itself at the forefront of peptide-powered molecular haircare, proving that the future of hair repair lies not in surface treatments – but in the biology of the strand itself.

By Shawn Sefton, MBA, RN

A circulator flips through a picklist that doesn’t match the back table. A surgeon asks for a device, and the nurse hesitates, “Is it even here?” A supply tech finds an expired implant just as the case is closing. The nurse tries to document the implant, but the scanner isn’t working and she can’t find it in the item master. Hours later, a revenue integrity analyst sits with unexplained and missed charges.

None of these moments make headlines. But together, they add up to stress in procedural rooms, missed revenue, unbudgeted waste, and hours of manual data entry. Hospitals can track a FedEx package from Memphis to Miami in real time. But the orthopedic plate placed in a patient yesterday? Sometimes it disappears into the system like it never existed.

Photo by RDNE Stock project: 

The status quo can’t keep up

OR and procedural room documentation systems are failing to keep pace with the realities of modern surgery. The problem isn’t that hospitals don’t try to record implants and supplies, it’s that even newer system designs struggle to capture every supply and implant, resulting in missing and unreliable data.

Manual documentation, whether electronic or on paper, depends on perfect input often during the most complex moments of a procedure. In reality, barcode scanners can fail and reconciliation happens hours, sometimes days, after the fact. As a result, up to 50% of the supplies and implants used in ORs go undocumented.

Meanwhile, reconciliation teams are left deciphering handwritten item numbers, trying to match unlabeled implants to the correct records, and often chasing down clinical team members long after a case ends just to ensure proper billing and records.

The result is incomplete, unreliable data that breaks the billing chain. Missed scans and documentation errors often mean items never make it onto the claim, directly translating into missed charges and lost revenue.

The impact?

Not only do missed charges create an administrative burden but hospitals can lose up to 30% of billable revenue tied to supplies and implants, a margin loss that would be unimaginable in any other industry.

What’s more, failing to accurately capture these items can introduce significant quality, regulatory, and patient safety risks, exactly the kinds of problems health systems try very hard to avoid.

What perioperative leaders are saying

With OBBBA requirements tightening margins, hospitals are under pressure to minimize waste, understand costs and protect profitability more than ever before. Because the OR drives up to 70% of hospital revenue, it’s no surprise that Becker’s first Perioperative Summit kept circling back to the topic of revenue.

Workforce relief is non-negotiable for hospitals that want to scale. When nurses and techs can anticipate surgeon needs, the OR hums. Delays vanish, substitutions shrink, cases flow and surgeons trust their team. Staff stress levels lower. As another leader put it, “Getting nurses away from the supply screen and back to anticipating the surgeon’s needs is the biggest win.”

While resolving missed OR and procedural room charges is critical, leaders also underscored the importance of integration. Technology must fit into daily workflows and EHRs if it’s going to stick in such a fast-paced environment. As one panelist emphasized, “If it doesn’t integrate and work for our people, it won’t scale.”

Many OR leaders are taking action but ultimately still missing far too many products due to systems that fail them, with one leader at Becker’s Perioperative conference saying, “The number of items that go unscanned every case is disturbing.”

However, one healthcare system decided to find a solution and the results are compelling.

How one hospital turned admin chaos into profit

Owensboro Health set out to audit and resolve this very problem. Their perioperative teams were grappling with manual, error-prone documentation in the OR. Nurses entered supply and implant data by hand, items slipped through the cracks, inventory data lagged, and billing teams spent hours chasing missed charges.

Determined to improve workflow and margins, Owensboro Health rolled out an AI-enabled automated supply and implant capture program across its ORs. The impact was significant:

• Delighted clinical, revenue integrity, and supply chain teams
• 48% reduction in monthly expired product costs
• 90%+ reduction in ERP inventory depletion errors
• 12% increase in monthly billable revenue

The volume of cases didn’t change. What changed was product and implant visibility. For staff, that meant fewer end-of-shift reconciliations and less administrative burden. For leaders, it meant millions in recovered revenue.

What should leaders do?

Many hospitals aim to close the OR documentation gap by adding extra staff processes and duplicative tracking systems. This looks like control but creates silos, extra work, and ultimately flawed data.

While plenty of AI tools overpromise, some were built to solve administrative problems like this. It is important to assess solutions carefully. Here are key ways to evaluate AI tools for perioperative documentation:

• Prioritize real-time integration—Does the solution capture data as cases unfold, or does it rely on manual reconciliation after the fact?
• Check workflow alignment—Can it fit seamlessly into existing OR workflows without adding screens and clicks for nurses and techs?
• Look for measurable impact—Can it demonstrate clear metrics, like improved item capture rates, reduced reconciliation time, case costing, expiry management or recovered revenue?
• Evaluate interoperability—Does it connect cleanly with your EHR, ERP, and billing systems, or does it create another silo?
• Test with frontline staff—Does it make the job easier for nurses, techs, and supply teams, or just shift work elsewhere?

Closing the loop

Every day, critical details in the OR slip through the cracks of manual systems. A recalled implant from last week’s surgery. A missed charge for a high-cost disposable. Small moments, easily overlooked, that quietly add up. They create blind spots that chip away at hospital margins, wear down staff, and skew reports that leaders rely on to make decisions. But this no longer has to be the norm. AI technology now gives hospitals the ability to see and capture what’s been missed. Hospitals that act can protect their margins, ease the load on their teams, and bring clarity back to the center of care. The gap is clear. The tools exist. It’s time to close the blind spots.

Shawn Sefton, MBA, RN, is Clinical Advisor at AssistIQ.

Study links support cells to improved cancer cluster survival in bloodstream  

HOUSTON, TX (March 27, 2026) – Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part because researchers lack reliable ways to recreate the conditions cancer cells encounter as they travel through the bloodstream.

Rice University bioengineers report a new platform designed to streamline one of the major challenges for metastasis research: Called the Advanced Tumor Landscape Analysis System, or ATLAS, the platform makes it easier to generate large quantities of cancer cell clusters that accurately model those involved in metastasis. Using the platform, the Rice team gained new insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.

Developed in the lab of Michael King, Rice’s E.D. Butcher Professor of Bioengineering, ATLAS builds on earlier work using superhydrophobic surfaces, i.e. materials that strongly repel water. When droplets containing cells are placed on these surfaces, they bead up rather than spread out, encouraging cells to stick to each other and produce three-dimensional clusters.

“Metastasis is still poorly understood because adequate laboratory techniques to recreate this complex process are lacking,” said King, a Cancer Prevention and Research Institute of Texas Scholar who also serves as special adviser to the provost on life science collaborations with the Texas Medical Center.

The King lab has been working for years on new high-throughput approaches of creating clusters of cancer cells, both on their own and alongside stromal cells, which are noncancerous but are frequently found in the tumor microenvironment. To study what happens during the metastatic process, the researchers expose these models to conditions that closely resemble those in the body ⎯ either via animal models or laboratory blood flow experiments.

Compared to earlier methods, ATLAS takes less time to deploy and costs less to produce. It uses 3D-printed microwell arrays that are treated to create the same kind of water-repelling effect seen in nature, such as on a lotus leaf.

“The way this is achieved, both in nature and in the laboratory, is to create a surface that is rough on a nanoscale level, and then to coat the nanoscale bumps with a nonwetting substance such as Teflon or wax,” said Alexandria Carter, a doctoral student in the King lab who is the first author on the study. “Here, we achieved this for the first time through 3D printing, which means the method is scalable and easily adoptable by other labs.”

Going beyond method development into actual testing, the researchers used ATLAS to create clusters of prostate cancer cells, including ones containing a type of stromal cell called cancer-associated fibroblasts, or CAFs. Testing revealed that cancer clusters are more likely to survive when traveling in groups, especially when CAFs are present. These support cells actively help cancer cells withstand the stresses of circulation and continue to grow.

“One of the most exciting elements of our paper is that it does not just report on a new experimental method for other researchers to use, but it also reports new fundamental biological results,” Carter said. “Perhaps in the future the next generation of prostate cancer drugs will target these CAF ‘escorts’ as a way to prevent metastasis.”

Carter recently completed the Rice Innovation Fellows program and is working on establishing a startup company called Bionostic to commercialize ATLAS. Run by Rice’s Liu Idea Lab for Innovation and Entrepreneurship (Lilie), the program trains doctoral students and postdoctoral researchers to translate their research into breakthrough solutions for real-world problems.

Kyle Judah, Lilie executive director, said “a pre-requisite for bringing research beyond the bench is to be deeply passionate about the problem space, and Carter is the perfect example of an exceptionally driven and committed engineer willing this idea into reality.”

Models that are both realistic and practical make possible research that would otherwise take longer and be costlier to undertake.

“ATLAS makes it easier to study one of the most dangerous aspects of cancer,” King said.

MISATO, JAPAN – 26 March 2026 – Zuellig Pharma today announced the successful relocation of its new clinical depot to Misato, strengthening its ability to deliver global quality standards with local operational agility and further strengthening its clinical supply capability across Asia Pacific. Japan remains one of the region’s preferred locations for clinical research, underpinned by its strong focus on medical advancement, rigorous ethical standards and commitment to healthcare.

Medical innovation across the region continues to accelerate, with China, India, Australia, Japan, South Korea, Taiwan and Singapore emerging as key pillars of Asia Pacific’s clinical trial ecosystem over the past five years^[1]. Against this backdrop, the move in Japan reinforces Zuellig Pharma’s commitment to supporting sponsors and clients with reliable, compliant and seamless access to Japan – advancing its broader mission to make healthcare more accessible.

The new depot will bring together Zuellig Pharma’s established knowledge assets, operational excellence, and clinical logistics and sourcing expertise. Backed by a highly experienced and expert-led local team, the depot delivers precision project management tailored to Japan’s intricate regulatory and logistical requirements, while enabling smoother coordination for multi-market studies as the clinical landscape continues to evolve.

“As sponsors and clients increasingly run multi-market studies, they need clinical supply partners that can deliver consistency across borders while navigating local complexity,” said John Graham, Chief Executive Officer, Zuellig Pharma. “This relocated depot will strengthen access to Japan within our regional network, helping us execute with greater reliability, compliance, and speed across the region.”

The Misato clinical depot will also provide a streamlined, turnkey solution for global sponsors seeking rapid and compliant market entry into Japan. Sponsors will benefit from the same rigorous operational excellence, regulatory adherence, and service consistency delivered by Zuellig Pharma’s strategic network of clinical depots, without the overhead of building or managing costly standalone facilities. This milestone supports Zuellig Pharma’s ongoing efforts to accelerate clinical development and improve patient access to innovative therapies across Asia Pacific.

With this strategic move, Zuellig Pharma further strengthens its position as a trusted partner for global clinical development, combining scale, expertise, and agility whilst delivering high-quality, compliant clinical logistics and sourcing solutions across Asia Pacific.

Harish Rana, known as one of the first individuals in India to be permitted passive euthanasia, passed away on Tuesday at the All India Institute of Medical Sciences (AIIMS), bringing an end to a long and difficult chapter that spanned over 13 years.

Rana, 31, had been in a coma since 2013 following a severe medical condition that left him unresponsive. For more than a decade, his life was sustained through continuous medical care, largely managed at his home in Ghaziabad by family members who remained by his side through the prolonged ordeal.

Earlier this month, on March 14, he was shifted to the palliative care unit of Dr. B.R. Ambedkar Institute Rotary Cancer Hospital at AIIMS-Delhi as his condition required specialized end-of-life support. Medical teams provided comfort care during his final days.

Rana’s case had drawn attention for its legal and ethical dimensions, particularly around the issue of passive euthanasia in India. It highlighted the emotional and financial strain faced by families caring for patients in prolonged vegetative states, while also bringing focus to the need for compassionate end-of-life care policies.

Despite the legal and medical complexities surrounding his condition, at the heart of the story was a family’s unwavering commitment. For years, his loved ones continued to hope, care, and advocate, navigating both personal grief and public attention.

His passing marks not just the end of a life, but the conclusion of a deeply human story—one that sparked conversations about dignity, medical ethics, and the realities of long-term critical care.

Harish Rana is remembered not only for the circumstances of his case but also for the quiet resilience shown by those who stood beside him throughout his journey.

New Delhi, Mar 25 (BNP): The Ministry of Ayush, in collaboration with the Department of Biotechnology (DBT), has announced a joint clinical study to evaluate Ayurveda as an adjunct therapy in tuberculosis (TB) treatment, marking a step toward integrative healthcare in India.

The announcement was made on World Tuberculosis Day at a high-level event held at Vigyan Bhawan, attended by senior policymakers, scientists, and healthcare experts.

Union Minister of State (Independent Charge) for Science and Technology, Dr. Jitendra Singh, said India is making steady progress in its fight against TB through science-driven innovation and integrated healthcare approaches.

“The collaborative clinical study reflects our commitment to evidence-based innovation, combining modern biomedical research with traditional knowledge systems,” he said, adding that efforts are also focused on addressing challenges such as drug resistance and undernutrition.

Minister of State (Independent Charge) for Ayush, Prataprao Jadhav, emphasised that TB treatment must go beyond eliminating infection to ensuring complete patient recovery and improved quality of life.

“With this approach, Ayurveda and other Ayush systems can play a supportive role in enhancing recovery, nutrition, and overall well-being,” he said.

The study, titled “Clinical Study on Ayurveda as an Adjunct Therapy for Tuberculosis”, will be conducted as a multi-centre trial across premier institutions, including AIIMS, JIPMER, and NEIGRIHMS.

Led by the Central Council for Research in Ayurvedic Sciences (CCRAS) in partnership with DBT, the 24-month study aims to assess the efficacy, safety, and tolerability of an Ayurveda regimen alongside standard anti-tuberculosis treatment (ATT), combined with nutritional support.

Officials said the initiative is expected to generate scientific evidence on improving recovery rates, nutritional outcomes, and quality of life among TB patients.

The programme also witnessed the exchange of a memorandum of understanding between BRIC-Translational Health Science and Technology Institute (THSTI) and CCRAS to formalise institutional collaboration.

The government reaffirmed its commitment to advancing evidence-based integrative healthcare solutions to tackle public health challenges and accelerate progress toward TB elimination.

CHENNAI, MARCH 22, 2026: Indian Hotels Company (IHCL), India’s largest hospitality company, continues to advance its sustainability and social impact agenda through Paathya, its ESG+ framework.

Photo caption: Dr. S. Armstrong, Vice-Chancellor Convener Committee, University of Madras, Megalina Iden, DC Traffic – East, and Ian Dubier, Area Director Operations for Tamil Nadu and General Manager of Taj Coromandel, flagging off IHCL’s Bharat EkSaath Walkathon at University of Madras in Chennai.

Marking its fourth year, IHCL reinforced its commitment to responsible tourism with Bharat EkSaath Walkathon – Tamil Nadu edition, an inclusive 3 km walk that brought together associates, their families, local partners, vendors and community members. This was held simultaneously across 14 countries in over 200 locations. The funds raised through the walkathon support the Taj Public Service Welfare Trust (TPSWT), reinforcing IHCL’s approach to social impact.

Teams from Taj Coromandel, Taj Connemara, Taj Club House, Taj Fisherman’s Cove Resort & Spa Chennai, Taj Wellington Mews Chennai, Vivanta Chennai IT Expressway, Ginger Chennai, OMR, Ginger Chennai, Vadapalani, Ginger Chennai, IITM, TajSATS, Vivanta Coimbatore, Savoy, Ooty – IHCL SeleQtions, Gateway Madurai and Gateway Coonoor participated in the 3-km walk.

The Walkathon commenced from the University of Madras and was flagged off by distinguished guests, Dr. S. Armstrong Vice-Chancellor Convener Committee, University of Madras, and Megalina Iden, DC Traffic – East. The route began at the University of Madras, proceeded along Madras Beach Road, and concluded back at the University campus.  The event concluded with a hearty breakfast, followed by the distribution of medals and certificates to all participants.

New Delhi, March 21 (BNP): The Ministry of Health and Family Welfare, through the National AIDS Control Organisation (NACO), convened the ‘Suraksha Sankalp Karyashala’ in Delhi to accelerate district-level HIV/AIDS response, with a focused approach on Haryana and the national capital.

The workshop, chaired by Rakesh Gupta, aimed to strengthen data-driven, district-specific strategies to improve prevention, testing, treatment, and overall service delivery for HIV/AIDS.

In his keynote address, Dr. Gupta stressed that HIV/AIDS continues to be a significant public health challenge, requiring coordinated and sustained efforts across all levels of governance. He highlighted the global 95:95:95 targets, which aim to ensure that 95 per cent of people living with HIV know their status, 95 per cent of those diagnosed receive treatment, and 95 per cent of those on treatment achieve viral suppression.

Reviewing current progress, officials noted that Delhi faces critical gaps, with only about 70 per cent of identified individuals linked to treatment, while Haryana has achieved an encouraging cascade of approximately 81:83:95, though further improvements are needed in diagnosis and treatment linkage.

The workshop also emphasised the elimination of mother-to-child transmission of HIV, which can be prevented through timely testing, counselling, and treatment during pregnancy, childbirth, and breastfeeding.

Officials said 219 districts across the country have been identified as priority areas for intensified HIV interventions, including 7 districts in Delhi and 11 in Haryana. District-level teams participated in the workshop to present progress, identify challenges, and develop targeted action plans.

Dr. Gupta called for a “whole-of-system” approach, urging stronger coordination between national, state, and district stakeholders to address gaps in awareness, testing, and treatment adherence.

He also outlined India’s goal of bringing HIV/AIDS under control by World AIDS Day 2027, with an enhanced target of achieving 95:95:99 metrics in the coming years.

The workshop forms part of India’s broader strategy to end AIDS as a public health threat by 2030, focusing on evidence-based interventions, improved treatment access, and reducing stigma and discrimination.